Conference Coverage

Big trial reassures on heart safety of testosterone in men


 

AT ENDO 2023

‘Big surprise’ and a mystery: Testosterone increased fracture risk

The fracture data were presented by Peter J. Snyder, MD, of the University of Pennsylvania, who earlier in the session had received an Endocrine Society award for his work in the testosterone field.

“No prior trial of testosterone treatment of hypogonadal men has been large enough or long enough to assess its effect on fractures ... until the TRAVERSE trial,” he said.

The hypothesis going in was that testosterone would decrease the fracture incidence, since prior data had suggested it improves many parameters of bone quality in elderly men and in those with severe hypogonadism.

Instead, there were 91 confirmed and adjudicated clinical fractures in the testosterone group versus 64 in the placebo group, giving a hazard ratio of 1.43 (P = .03). The risk was seen across fracture types, increasing the likelihood that this finding was, in fact, real, Dr. Snyder said.

“We could speculate about a possible mechanism, but because we did not expect these results, we did not design the trial to evaluate a possible mechanism,” Dr. Snyder noted.

Dr. Anawalt told this news organization that the fracture finding “was a big surprise. None of us would have expected that there would be an increase in fractures.”

Clinically, Dr. Anawalt said it suggests consideration of expanding the use of anti-osteoporotic medication such as bisphosphonates to men with low testosterone and elevated fracture risk for whom clinicians may have assumed that just giving them testosterone replacement might also protect their bones.

“This begs the question should we reorient the way we’re thinking about these men.”

The study was funded by AbbVie, Acerus Pharmaceuticals Corporation/Aytu Biosciences, Allergan Sales, Endo Pharmaceuticals, and Upsher-Smith Laboratories. Dr. Bhasin has disclosed grants to his institution from Function Promoting Therapies and Metro International Biotech, and owns stock in XYone. Dr. Anawalt has reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

This article was updated 6/19/23.

Pages

Recommended Reading

A hormone that can predict male long-term health
MDedge Endocrinology
Getting testosterone online is easy. Solid advice, not so much
MDedge Endocrinology
Can a Mediterranean diet ease depression in young men?
MDedge Endocrinology
New osteoporosis guideline says start with a bisphosphonate
MDedge Endocrinology
Can a hormone shot rescue low libido?
MDedge Endocrinology
Three surprising studies on exercise restriction and an exercise sweet spot
MDedge Endocrinology
Factors linked with increased VTE risk in COVID outpatients
MDedge Endocrinology
COVID can mimic prostate cancer symptoms
MDedge Endocrinology
Prostate cancer drug shortage leaves some with uncertainty
MDedge Endocrinology
FDA approves first-ever OTC erectile dysfunction gel
MDedge Endocrinology